title: The effectiveness of transdermal electromotive administration with verapamil and dexamethasone in the treatment of Peyronie's disease.
abstract: OBJECTIVE
  To determine the effectiveness of transdermal electromotive administration (TEA) of verapamil and dexamethasone in the treatment of Peyronie's disease (PD).
  
  
  METHODS
  Totally, 51 patients with PD were prospectively included in the study. All patients were evaluated by history, subjective score scales, physical examination, photographs, and penile USG, before and after therapy. All patients were treated with TEA of the combination of verapamil and dexamethasone. The treatment plan included a total of 20 sessions (at 3-day intervals for a period of 2 months), each with a duration of 20 min. At the end of the study, improvements in penile plaques, penile deviation, pain on erection, and erectile dysfunction were determined.
  
  
  RESULTS
  The findings in 41 of the 51 patients were eligible to present. Median patient age was 52 years. Median duration of disease at presentation was 8 months. Remarkable reduction in palpable plaques and in penile angulation was observed in 10 patients (24%) and 11 (26%) patients, respectively. There were significant decreases in median plaque volume from 72 mm(2) to 45 mm(2) (P < 0.001), and in median penile angulation from 25 degrees to 15 degrees (P < 0.001). Impaired sexual activity and pain on erection had completely resolved in 11 (55%) patients and in 16 (80%), respectively.
  
  
  CONCLUSIONS
  The results of our study have shown that TEA of the combination of verapamil and dexamethasone is a more effective therapy for improving subjective symptoms rather than objective symptoms. Therefore, we think that this treatment can be individualized according to the clinical features of PD patients.
authors.affiliation: Department of Urology, S.B. Diskapi Yildirim Beyazit Training and Research Hospital, Hosdere Caddesi, 115/72 Yukari-Ayranci, Ankara, 06550, Turkey, tuyguncan@yahoo.com.
authors.forename: Can
authors.initials: C
authors.lastname: Tuygun
authors.forename: Ugur Hakki
authors.initials: UH
authors.lastname: Ozok
authors.forename: Adnan
authors.initials: A
authors.lastname: Gucuk
authors.forename: I Halil
authors.initials: IH
authors.lastname: Bozkurt
authors.forename: M Abdurrahim
authors.initials: MA
authors.lastname: Imamoglu
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D002121:Calcium Channel Blockers / Q000008:administration & dosage*; D003907:Dexamethasone / Q000008:administration & dosage*; D053672:Electrochemotherapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D010411:Penile Induration / Q000188:drug therapy*; D011446:Prospective Studies; D014700:Verapamil / Q000008:administration & dosage*
chemical_list: D000893:Anti-Inflammatory Agents; D002121:Calcium Channel Blockers; D003907:Dexamethasone; D014700:Verapamil